Effectiveness, safety and tolerability of ozenoxacin 2% lotion vs. clindamycin 1% lotion in mild-to-moderate truncal acne: an open-label randomized controlled clinical trial
Clinical and Experimental Dermatology · 28.08.2026
DOI: 10.1093/ced/llag372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 28.08.2026. Verfasst von Anupam Das und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Truncal acne is a frequently encountered but relatively understudied manifestation of acne vulgaris and is often associated with significant physical discomfort and psychosocial impact. Topical clindamycin has been used extensively in mild-to-moderate acne; however, there are concerns regarding antimicrobial resistance, which has prompted interest in alternative topical agents. Ozenoxacin, a nonfluorinated quinolone, offers broad-spectrum antibacterial activity with minimal systemic absorption.
Objectives
To compare the effectiveness, safety and tolerability of ozenoxacin 2% lotion with clindamycin 1% lotion in patients with mild-to-moderate truncal acne.
Methods
This institution-based, open-label, randomized controlled trial (registered with the Clinical Trials Registry of India: CTRI/2025/02/080133) included 78 patients aged 18–35 years with mild-to-moderate truncal acne. Participants were randomized to receive either ozenoxacin 2% lotion or clindamycin 1% lotion applied twice daily for 12 weeks. Both groups received adapalene 0.1% gel for once-daily application at bedtime. Clinical efficacy and quality of life were assessed using total, inflammatory and noninflammatory lesion counts, and the Investigator Global Assessment, Cardiff Acne Disability Index and Dermatology Life Quality Index scores. Safety was evaluated through adverse event monitoring.
Results
Thirty-five patients in the ozenoxacin group and 34 in the clindamycin group completed the study. Both groups demonstrated statistically significant improvement from baseline in all efficacy parameters at 12 weeks (P < 0.05). Intergroup comparisons showed no statistically significant differences across clinical or quality-of-life outcomes. Both treatments were well tolerated, with only mild and transient adverse effects reported.
Conclusions
Ozenoxacin demonstrated comparable efficacy and tolerability to clindamycin when used in combination with adapalene in truncal acne.
Autor:innen und Institutionen
- Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India.
- Department of Dermatology, Diamond Harbour Government Medical College and Hospital, West Bengal, India.
ORCID-Profile: Anupam Das
Zitieren
APA
Das, A., Chatterjee, S., Banerjee, S., & Sengupta, S. (2026). Effectiveness, safety and tolerability of ozenoxacin 2% lotion vs. clindamycin 1% lotion in mild-to-moderate truncal acne: an open-label randomized controlled clinical trial. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag372
Vancouver
Das A, Chatterjee S, Banerjee S, Sengupta S. Effectiveness, safety and tolerability of ozenoxacin 2% lotion vs. clindamycin 1% lotion in mild-to-moderate truncal acne: an open-label randomized controlled clinical trial. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag372
BibTeX
@article{Das2026,
author = {Das, Anupam and Chatterjee, Sambit and Banerjee, Saikat and Sengupta, Sujata},
title = {Effectiveness, safety and tolerability of ozenoxacin 2% lotion vs. clindamycin 1% lotion in mild-to-moderate truncal acne: an open-label randomized controlled clinical trial},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag372}
}
EUVIMED